MANE Veradermics, Incorporated logo

MANE Veradermics, Incorporated

Healthcare
$101.62-2.94%ClosedMarket Cap: $4.25B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

9.68

P/S

0.00

EV/EBITDA

-70.00

DCF Value

$0.60

FCF Yield

-1.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-95.4%

ROA

-13.7%

ROIC

-15.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-27.2M$
Q4 null$0.00$-21.8M$
FY null$0.00$-70.0M$
Q4 null$0.00$-5.7M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$75.00

Target (Median)

$75.00

Target Range

$75.00 - $75.00

0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
CitigroupBuy
2026-05-18
Leerink PartnersOutperform
2026-04-22

Latest News

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

0.00

Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.

Peers